Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 18/20 | 1.00 |
| ▸ | F12 | P00748 | 1/20 | 1.00 |
| ▸ | PLAT | P00750 | 1/20 | 1.00 |
| ▸ | PROC | P04070 | 1/20 | 1.00 |
| ▸ | F7 | P08709 | 1/20 | 1.00 |
| ▸ | CTRB1 | P17538 | 1/20 | 1.00 |
| ▸ | CTRL | P40313 | 1/20 | 1.00 |
| ▸ | CTRB2 | Q6GPI1 | 1/20 | 1.00 |
| ▸ | CTRC | Q99895 | 1/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 19/20 | 0.90 |
| ▸ | F9 | P00740 | 15/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15597198 | 1.00 | F11 (1.00) | F11F12PLATPROCF7 | |
| SCHEMBL15456517 | 1.00 | F11 (1.00) | F11F12PLATPROCF7 | |
| SCHEMBL15597251 | 1.00 | F11 (1.00) | F11F12PLATPROCF7 | |
| SCHEMBL15456413 | 1.00 | F11 (1.00) | F11F12PLATPROCF7 | |
| SCHEMBL18536117 | 0.94 | KLKB1 (1.00) | F11F12PLATPROCF7 | |
| SCHEMBL15594051 | 0.94 | KLKB1 (1.00) | F11F12PLATPROCF7 | |
| SCHEMBL15594137 | 0.94 | F11 (1.00) | F11F12PLATPROCF7 | |
| SCHEMBL17991856 | 0.94 | KLKB1 (1.00) | F11F12PLATPROCF7 | |
| SCHEMBL16910511 | 0.94 | F11 (0.91) | F11F12PLATPROCF7 | |
| SCHEMBL18124051 | 0.94 | F11 (0.91) | F11F12PLATPROCF7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2882734-B1 | DIHYDROPYRIDONE AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-12 | — | — | EP | disclosed |
| US-9376444-B2 | Dihydropyridone P1 as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150166550-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166550-A1 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | F11 3/4885F12 4/4885PLAT 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.